Patents by Inventor Michelle Lynn HALL

Michelle Lynn HALL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNA POLYMERASE VARIANTS FOR CO-TRANSCRIPTIONAL CAPPING
    Publication number: 20230104080
    Abstract: The present disclosure provides RNA polymerase variants for high efficiency transcription.
    Type: Application
    Filed: August 1, 2022
    Publication date: April 6, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Athanasios Dousis, Kanchana Ravichandran, Amy E. Rabideau, Margaret Franklin, Kevin Smith, Michelle Lynn Hall
  • RNA polymerase variants for co-transcriptional capping
    Patent number: 11485960
    Abstract: The present disclosure provides RNA polymerase variants for high efficiency transcription.
    Type: Grant
    Filed: May 20, 2021
    Date of Patent: November 1, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Athanasios Dousis, Kanchana Ravichandran, Amy E. Rabideau, Margaret Franklin, Kevin Smith, Michelle Lynn Hall
  • Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
    Patent number: 10548864
    Abstract: The invention features all-trans retinoic acid (ATRA)-related compounds capable of associating with Pin1 and methods of treating a proliferative disorder characterized by elevated Pin1 marker levels, Pin1 degradation, and/or reduced Pin1 Ser71 phosphorylation in a subject by administering an ATRA-related compound. The invention also features methods of treating proliferative disorders, autoimmune diseases, and addiction conditions (e.g., diseases, disorders, and conditions characterized by elevated Pin1 marker levels) by administering an ATRA-related compound in combination with another therapeutic compound.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: February 4, 2020
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Kun Ping Lu, Xiao Zhen Zhou, Shuo Wei, Lijun Sun, Michelle Lynn Hall
  • ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS
    Publication number: 20180064666
    Abstract: The invention features all-trans retinoic acid (ATRA)-related compounds capable of associating with Pin1 and methods of treating a proliferative disorder characterized by elevated Pin1 marker levels, Pin1 degradation, and/or reduced Pin1 Ser71 phosphorylation in a subject by administering an ATRA-related compound. The invention also features methods of treating proliferative disorders, autoimmune diseases, and addiction conditions (e.g., diseases, disorders, and conditions characterized by elevated Pin1 marker levels) by administering an ATRA-related compound in combination with another therapeutic compound.
    Type: Application
    Filed: March 10, 2016
    Publication date: March 8, 2018
    Inventors: Kun Ping LU, Xiao Zhen ZHOU, Shuo WEI, Lijun SUN, Michelle Lynn HALL